serum lipoprotein profiles and response to pegylated interferon plus ribavirin combination therapy in patients with chronic hcv genotype 1b infection
نویسندگان
چکیده
conclusions examination of the fasting lipid profile has clinical importance in predicting the efficacy of peg-ifn-α-2b plus rbv combination therapy for patients with hcv g1b even after the discovery of the il28 genotype as a potent predictive factor. objectives to re-examine the significance of lipoprotein profiles on virological response to peg-ifn plus rbv combination therapy in patients with chronic hcv g1b infection, we examined cholesterol and triglyceride concentrations in each lipoprotein fraction separated by high performance liquid chromatography. background abnormal serum lipid profiles have been noted in patients with chronic hepatitis c virus (hcv) infection. moreover, many reports suggest that serum lipoprotein profiles are more profoundly distorted in patients with hcv g1b infection who have an unfavorable response to pegylated interferon (peg-ifn) plus ribavirin (rbv) combination therapy. however, after the discovery of single nucleotide polymorphisms near the il28b gene (rs8099917 and rs12979860) as potent predictive factors affecting the response to peg-ifn plus rbv, lipid factors are thought to be confounding factors. results an increased ratio of cholesterol/triglyceride in very low-density lipoprotein (odds ratio (or) 3.03; 95% confidence interval (ci) 1.01-9.44) along with a major genotype of rs8099917 (or 9.09; 95% ci 2.94-33.33), were independent predictive factors for svr. in contrast, lipid factors were not elucidated as independent predictive factors for nvr. patients and methods lipoprotein profiles were examined using fasting sera from 108 patients infected with hcv g1b who had chronic hepatitis, as determined by liver biopsy. results of lipoprotein profiles and clinical data, including il28b genotype and amino acid substitution at aa70 of hcv g1b, were compared between patients with a sustained virological response (svr) and non-svr or a non-virological response (nvr) and virological responses other than nvr (non-nvr). in addition, significant predictive factors independently associated with virological response to peg-ifnα-2b plus rbv were determined by logistic regression analysis.
منابع مشابه
Serum Lipoprotein Profiles and Response to Pegylated Interferon Plus Ribavirin Combination Therapy in Patients With Chronic HCV Genotype 1b Infection
BACKGROUND Abnormal serum lipid profiles have been noted in patients with chronic hepatitis C virus (HCV) infection. Moreover, many reports suggest that serum lipoprotein profiles are more profoundly distorted in patients with HCV G1b infection who have an unfavorable response to pegylated interferon (peg-IFN) plus ribavirin (RBV) combination therapy. However, after the discovery of single nucl...
متن کاملSTARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection.
BACKGROUND & AIMS The efficacy and tolerability of faldaprevir, a potent hepatitis C virus (HCV) NS3/4A protease inhibitor, plus peginterferon (PegIFN) and ribavirin (RBV) was assessed in a double-blind, placebo-controlled phase 3 study of treatment-naïve patients with HCV genotype-1 infection. METHODS Patients were randomly assigned (1:2:2) to PegIFN/RBV plus: placebo (arm 1, n = 132) for 24...
متن کاملchanges in serum interleukin-33 concentration before and after treatment with pegylated interferon alfa-2a plus ribavirin in patients with chronic hepatitis c genotype 1b infection
background il-33 is a novel member of the il-1 family, which has been shown to play an important role in t helper 2 (th2)-associated immune responses. recent studies have suggested a possible role for il-33 in the pathogenesis of liver damage during acute and chronic hepatitis; furthermore, il-33 may be involved in the development and progression of liver fibrosis. objectives to evaluate serum ...
متن کاملLiver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C.
BACKGROUND AND AIMS The gold standard treatment of chronic hepatitis C (CHC) is combined pegylated interferon and ribavirin. Considering side effects and treatment cost, prediction of treatment response before therapy is important. The aim of this study was to identify a liver gene signature to predict sustained virological response in patients with CHC. METHODS Group A (training set) compris...
متن کاملIFI35, mir-99a and HCV Genotype to Predict Sustained Virological Response to Pegylated-Interferon Plus Ribavirin in Chronic Hepatitis C
Although, the treatment of chronic hepatitis C (CHC) greatly improved with the use of direct antiviral agents, pegylated-interferon (PEG-IFN) plus ribavirin remains an option for many patients, worldwide. The intra-hepatic level of expression of interferon stimulated genes (ISGs) and the rs12979860 CC genotype located within IFNL3 have been associated with sustained virological response (SVR), ...
متن کاملمنابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
hepatitis monthlyجلد ۱۳، شماره ۵، صفحات ۰-۰
میزبانی شده توسط پلتفرم ابری doprax.com
copyright © 2015-2023